Fate Therapeutics, Inc.
FATE
$1.06
-$0.07-6.20%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -136.32M | -156.09M | -171.52M | -175.88M | -186.26M |
| Total Depreciation and Amortization | 12.90M | 14.65M | 16.03M | 17.47M | 18.96M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 21.07M | 37.58M | 43.96M | 43.02M | 46.38M |
| Change in Net Operating Assets | -3.74M | -6.71M | -4.08M | -7.95M | -1.96M |
| Cash from Operations | -106.08M | -110.57M | -115.61M | -123.33M | -122.87M |
| Capital Expenditure | -5.95M | -4.86M | -3.15M | -1.84M | -730.00K |
| Sale of Property, Plant, and Equipment | 362.00K | 125.00K | 122.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 116.76M | 111.09M | 113.57M | 39.42M | 12.95M |
| Cash from Investing | 111.17M | 106.35M | 110.54M | 37.58M | 12.22M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 0.00 | 0.00 | 0.00 | 75.49M |
| Repurchase of Common Stock | -- | -- | -- | -666.00K | -666.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 5.49M | 6.93M | 4.46M | 5.07M | 25.07M |
| Cash from Financing | 5.49M | 6.93M | 4.46M | 4.40M | 99.89M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.57M | 2.71M | -618.00K | -81.35M | -10.76M |